Raquel Samões, Ana Cavalheiro, Maria Manuel Tavares, Catarina Teixeira, Bárbara Leal, João Chaves, Sara Cavaco
{"title":"改良阿特金斯饮食停止治疗成人耐药癫痫的动机和预测因素。","authors":"Raquel Samões, Ana Cavalheiro, Maria Manuel Tavares, Catarina Teixeira, Bárbara Leal, João Chaves, Sara Cavaco","doi":"10.1111/epi.18657","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study was undertaken to explore the motives and predictors of modified Atkins diet (MAD) discontinuation as a treatment of adults with drug-resistant epilepsy (DRE).</p><p><strong>Methods: </strong>A single-center observational longitudinal study was made of a cohort of patients treated with MAD during the first 6 years at a multidisciplinary outpatient clinic dedicated to adult patients. Time to MAD discontinuation analyses were used to explore sociodemographic, clinical, and biochemical predictors of MAD persistence.</p><p><strong>Results: </strong>Eighty patients initiated MAD (54% females, median age = 29 years, median epilepsy duration = 21 years, median baseline seizure frequency = 30/month, median antiseizure medications = 4, 68% focal epilepsy, 64% structural etiology, and 26% genetic cause). The patients used the diet for a median time of 122 days. Fifteen percent of patients were very early dropouts (before 30 days), 20% were early dropouts (30-89 days), and 17.5% were late dropouts (>365 days). The motives for dropout (n = 64) were noncompliance (34.4%), inefficacy (23.4%), side effects (23.4%), and diet tiredness (18.8%). Female sex (adjusted hazard ratio [HR] = 1.75, p = .042), focal seizures with preserved consciousness (adjusted HR = 2.69, p = .017), higher glycemic level at baseline (adjusted HR = 1.03, p = .044), and lower level of serum total proteins at baseline (adjusted HR = .55, p = .052) were associated with shorter persistence on MAD. The HR for discontinuation was also higher for patients without daily seizures (HR = 1.72, p = .038). Among patients with at least 3 months in MAD (n = 51), reduced clinical response at month 3 was associated with earlier discontinuation of MAD, as measured by lower percent seizure reduction (HR = .98, p = .004) and <50% seizure reduction (HR = 2.44, p = .027).</p><p><strong>Significance: </strong>The dropout rate of MAD in adults with DRE is high even at dedicated centers. Females, patients with less severe epilepsies, and patients previously on carbohydrate-based diets may be more prone to earlier dropouts. These patients require closer monitoring in specialized ketogenic diet clinics to prevent MAD discontinuation before the minimum period necessary to evaluate response.</p>","PeriodicalId":11768,"journal":{"name":"Epilepsia","volume":" ","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Motives and predictors of modified Atkins diet discontinuation as treatment of adults with drug-resistant epilepsy.\",\"authors\":\"Raquel Samões, Ana Cavalheiro, Maria Manuel Tavares, Catarina Teixeira, Bárbara Leal, João Chaves, Sara Cavaco\",\"doi\":\"10.1111/epi.18657\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study was undertaken to explore the motives and predictors of modified Atkins diet (MAD) discontinuation as a treatment of adults with drug-resistant epilepsy (DRE).</p><p><strong>Methods: </strong>A single-center observational longitudinal study was made of a cohort of patients treated with MAD during the first 6 years at a multidisciplinary outpatient clinic dedicated to adult patients. Time to MAD discontinuation analyses were used to explore sociodemographic, clinical, and biochemical predictors of MAD persistence.</p><p><strong>Results: </strong>Eighty patients initiated MAD (54% females, median age = 29 years, median epilepsy duration = 21 years, median baseline seizure frequency = 30/month, median antiseizure medications = 4, 68% focal epilepsy, 64% structural etiology, and 26% genetic cause). The patients used the diet for a median time of 122 days. Fifteen percent of patients were very early dropouts (before 30 days), 20% were early dropouts (30-89 days), and 17.5% were late dropouts (>365 days). The motives for dropout (n = 64) were noncompliance (34.4%), inefficacy (23.4%), side effects (23.4%), and diet tiredness (18.8%). Female sex (adjusted hazard ratio [HR] = 1.75, p = .042), focal seizures with preserved consciousness (adjusted HR = 2.69, p = .017), higher glycemic level at baseline (adjusted HR = 1.03, p = .044), and lower level of serum total proteins at baseline (adjusted HR = .55, p = .052) were associated with shorter persistence on MAD. The HR for discontinuation was also higher for patients without daily seizures (HR = 1.72, p = .038). Among patients with at least 3 months in MAD (n = 51), reduced clinical response at month 3 was associated with earlier discontinuation of MAD, as measured by lower percent seizure reduction (HR = .98, p = .004) and <50% seizure reduction (HR = 2.44, p = .027).</p><p><strong>Significance: </strong>The dropout rate of MAD in adults with DRE is high even at dedicated centers. Females, patients with less severe epilepsies, and patients previously on carbohydrate-based diets may be more prone to earlier dropouts. These patients require closer monitoring in specialized ketogenic diet clinics to prevent MAD discontinuation before the minimum period necessary to evaluate response.</p>\",\"PeriodicalId\":11768,\"journal\":{\"name\":\"Epilepsia\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":6.6000,\"publicationDate\":\"2025-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Epilepsia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/epi.18657\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epilepsia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/epi.18657","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:本研究旨在探讨改良阿特金斯饮食(MAD)停止治疗成人耐药癫痫(DRE)的动机和预测因素。方法:一项单中心观察性纵向研究对前6年在多学科门诊专门为成人患者治疗的MAD患者进行了队列研究。MAD停药时间分析用于探讨MAD持续存在的社会人口学、临床和生化预测因素。结果:80例患者首发为MAD(54%为女性,中位年龄29岁,中位癫痫持续时间21年,中位基线发作频率30次/月,中位抗癫痫药物4次,局灶性癫痫68%,结构病因64%,遗传病因26%)。患者使用这种饮食的中位时间为122天。15%的患者为早期辍学(30天前),20%为早期辍学(30-89天),17.5%为晚期辍学(365天)。退出治疗的原因(n = 64)分别为不遵医术(34.4%)、无效(23.4%)、副作用(23.4%)和饮食疲劳(18.8%)。女性(校正风险比[HR] = 1.75, p =。042),局灶性癫痫发作伴意识保留(调整后HR = 2.69, p =。017),基线时较高的血糖水平(调整后的风险比= 1.03,p =。044),血清总蛋白水平低于基线(调整后的HR =。55, p =。052)与MAD持续时间较短相关。无每日癫痫发作的患者停药的HR也较高(HR = 1.72, p = 0.038)。在至少3个月的MAD患者中(n = 51),第3个月的临床反应降低与早期停止MAD相关,以较低的癫痫发作减少百分比(HR =)来衡量。98, p =。意义:即使在专门的中心,患有DRE的成人的MAD辍学率也很高。女性、癫痫不太严重的患者和以前以碳水化合物为基础的饮食的患者可能更容易提前退出。这些患者需要在专门的生酮饮食诊所进行更密切的监测,以防止在评估反应所需的最短时间之前停用MAD。
Motives and predictors of modified Atkins diet discontinuation as treatment of adults with drug-resistant epilepsy.
Objective: This study was undertaken to explore the motives and predictors of modified Atkins diet (MAD) discontinuation as a treatment of adults with drug-resistant epilepsy (DRE).
Methods: A single-center observational longitudinal study was made of a cohort of patients treated with MAD during the first 6 years at a multidisciplinary outpatient clinic dedicated to adult patients. Time to MAD discontinuation analyses were used to explore sociodemographic, clinical, and biochemical predictors of MAD persistence.
Results: Eighty patients initiated MAD (54% females, median age = 29 years, median epilepsy duration = 21 years, median baseline seizure frequency = 30/month, median antiseizure medications = 4, 68% focal epilepsy, 64% structural etiology, and 26% genetic cause). The patients used the diet for a median time of 122 days. Fifteen percent of patients were very early dropouts (before 30 days), 20% were early dropouts (30-89 days), and 17.5% were late dropouts (>365 days). The motives for dropout (n = 64) were noncompliance (34.4%), inefficacy (23.4%), side effects (23.4%), and diet tiredness (18.8%). Female sex (adjusted hazard ratio [HR] = 1.75, p = .042), focal seizures with preserved consciousness (adjusted HR = 2.69, p = .017), higher glycemic level at baseline (adjusted HR = 1.03, p = .044), and lower level of serum total proteins at baseline (adjusted HR = .55, p = .052) were associated with shorter persistence on MAD. The HR for discontinuation was also higher for patients without daily seizures (HR = 1.72, p = .038). Among patients with at least 3 months in MAD (n = 51), reduced clinical response at month 3 was associated with earlier discontinuation of MAD, as measured by lower percent seizure reduction (HR = .98, p = .004) and <50% seizure reduction (HR = 2.44, p = .027).
Significance: The dropout rate of MAD in adults with DRE is high even at dedicated centers. Females, patients with less severe epilepsies, and patients previously on carbohydrate-based diets may be more prone to earlier dropouts. These patients require closer monitoring in specialized ketogenic diet clinics to prevent MAD discontinuation before the minimum period necessary to evaluate response.
期刊介绍:
Epilepsia is the leading, authoritative source for innovative clinical and basic science research for all aspects of epilepsy and seizures. In addition, Epilepsia publishes critical reviews, opinion pieces, and guidelines that foster understanding and aim to improve the diagnosis and treatment of people with seizures and epilepsy.